NCT06065748 2026-04-06A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Hoffmann-La RochePhase 3 Recruiting1,050 enrolled
NCT07492641 2026-03-25BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseBeOne MedicinesPhase 3 Not yet recruiting1,056 enrolled
NCT07174336 2026-03-20A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)Eli Lilly and CompanyPhase 3 Recruiting920 enrolled
NCT04546009 2026-02-20A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)Hoffmann-La RochePhase 3 Active not recruiting992 enrolled
NCT06757634 2026-02-05Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)Celcuity IncPhase 3 Recruiting674 enrolled
NCT02297438 2025-10-27A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]PfizerPhase 3 Completed340 enrolled 29 charts
NCT02600923 2022-01-20Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed AppropriatePfizerPhase 3 Completed131 enrolled 12 charts